Skip to main content
Clinical Trials/NCT00609193
NCT00609193
Completed
N/A

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania Following Successful Treatment With Lithium or Quetiapine

University of Cincinnati1 site in 1 country81 target enrollmentJanuary 2008

Overview

Phase
N/A
Intervention
lithium
Conditions
Bipolar Disorder
Sponsor
University of Cincinnati
Enrollment
81
Locations
1
Primary Endpoint
The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium.
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium. Both of these medicines are FDA-approved to treat mania in adults and lithium is also FDA approved in children; quetiapine is commonly used in children with mania, but is not FDA approved for this indication in this age group.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
July 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stephen Strakowski

Academic Director of Medicine

University of Cincinnati

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

1

Study subjects receiving lithium

Intervention: lithium

2

Study subjects receiving quetiapine

Intervention: quetiapine

Outcomes

Primary Outcomes

The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium.

Time Frame: 8 weeks

Study Sites (1)

Loading locations...

Similar Trials